|
Suarez EU, Boluda B, Lavilla E, Tormo M, Botella C, Gil C, Vives S, Rodriguez C, Serrano J, Sayas MJ, Martinez-Sanchez P, Ramos F, Bernal T, Algarra L, Bergua-Burgues JM, Perez-Simon JA, Herrera P, Barrios M, Noriega-Concepcion V, Raposo-Puglia JA, Ayala R, Barragan E, Martinez-Cuadron D, Amigo ML, Lopez-Lorenzo JL, Lazaro-Garcia A, Guimaraes JE, Colorado M, Garcia-Boyero R, De Rueda-Ciller B, Foncillas-Garcia M, Hong A, Labrador J, Alonso-Dominguez JM, Montesinos P; PETHEMA group. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens? Ann Hematol. 2024 Aug;103(8):2845-2851. doi: 10.1007/s00277-024-05840-7. Epub 2024 Jun 17. PubMed PMID: 38884787.
AÑO: 2024; IF: 3.0
|
38884787
|
Diez-Campelo M, Lopez-Cadenas F, Xicoy B, Lumbreras E, Gonzalez T, Del Rey Gonzalez M, Sanchez-Garcia J, Coll Jorda R, Slama B, Hernandez-Rivas JA, Thepot S, Bernal T, Guerci-Bresler A, Bargay J, Amigo ML, Preudhomme C, Fenwarth L, Platzbecker U, Gotze KS, Arar A, Toribio S, Del Canizo C, Hernandez-Rivas JM, Fenaux P. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial. Lancet Haematol. 2024 Sep;11(9):e659-e670. doi: 10.1016/S2352-3026(24)00142-X. Epub 2024 Jul 18. PubMed PMID: 39033767.
AÑO: 2024; IF: 15.4
|
|
Martinez-Cuadron D, Megias-Vericat JE, Gil C, Bernal T, Tormo M, Martinez-Sanchez P, Rodriguez-Medina C, Serrano J, Herrera P, Simon JAP, Sayas MJ, Bergua J, Lavilla-Rubira E, Amigo ML, Benavente C, Lorenzo JLL, Perez-Encinas MM, Vidriales MB, Colorado M, De Rueda B, Garcia-Boyero R, Marini S, Garcia-Suarez J, Lopez-Pavia M, Gomez-Roncero MI, Noriega V, Lopez A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, Montesinos P. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry. Haematologica. 2024 Jan 1;109(1):115-128. doi: 10.3324/haematol.2022.282506. PubMed PMID: 37199127; PubMed Central PMCID: PMC10772508.
AÑO: 2024; IF: 8.2
|
|
Labrador J, Martinez-Cuadron D, Boluda B, Serrano J, Gil C, Perez-Simon JA, Bernal T, Bergua JM, Martinez-Lopez J, Rodriguez-Medina C, Vidriales MB, Garcia-Boyero R, Algarra L, Polo M, Sayas MJ, Tormo M, Alonso-Dominguez JM, Herrera P, Lavilla E, Ramos F, Amigo ML, Vives-Polo S, Rodriguez-Macias G, Mena-Duran A, Perez-Encinas MM, Arce-Fernandez O, Cuello R, Sanchez-Garcia J, Gomez-Casares MT, Chillon MC, Calasanz MJ, Ayala R, Rodriguez-Veiga R, Barragan E, Montesinos P; PETHEMA Group. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry. Cancer. 2024 Oct 15;130(20):3436-3451. doi: 10.1002/cncr.35431. Epub 2024 Jun 19. PubMed PMID: 38896056.
AÑO: 2024; IF: 6.1
|
|
Martinez-Cuadron D, Megias-Vericat JE, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C, Aguiar E, Bergua J, Lopez-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodriguez-Medina C, Lopez-Pavia M, Tormo M, Algarra L, Amigo ML, Sayas MJ, Labrador J, Rodriguez-Gutierrez JI, Benavente C, Costilla-Barriga L, Garcia-Boyero R, Lavilla-Rubira E, Vives S, Herrera P, Garcia-Belmonte D, Herraez MM, Vasconcelos Esteves G, Gomez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MA, Montesinos P. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. PubMed PMID: 34794172; PubMed Central PMCID: PMC8864639.
AÑO: 2022; IF: 7.5
|